According to insiders, the FDA is aiming to fully approve Pfizer-BioNTech’s COVID-19 vaccine by next month, potentially before Labor Day. This move comes as the highly transmissible delta variant continues to surge across the U.S., leading to rising case numbers and hospitalizations. While vaccination rates have seen a slight uptick, they still fall short of the peak levels observed in April, when approximately 3.5 million doses were being administered daily.
The FDA has reportedly expedited its process for granting full approval, responding to President Biden’s expectations for a fall approval timeline. The agency confirmed it is taking a comprehensive approach to finalize the vaccine approval. Full FDA authorization could significantly enhance public confidence in the vaccine’s safety and effectiveness, prompting institutions like universities, hospitals, and the military to implement new vaccine mandates once approval is granted.
Currently, around 192 million Americans have received at least one dose of a COVID-19 vaccine, which represents roughly 58% of the total population and 70% of adults. However, daily new COVID-19 cases have surged to an average of 86,000, marking a 142% increase from just two weeks earlier.
A recent survey by the Kaiser Family Foundation indicated that 30% of unvaccinated individuals said they would be more inclined to get vaccinated if the vaccine received full FDA approval. Nevertheless, the FDA cautioned that some may be using the approval as an excuse to avoid vaccination amid familial and societal pressure.
For more insights into home insemination and pregnancy resources, check out this blog post or learn from this authority on the topic. If you’re looking for more information on home insemination, this resource is excellent.
Potential Search Queries:
- Home insemination kit
- How to self inseminate
- Insemination syringe for home use
- Best practices for home insemination
- Pregnancy tips for home insemination
In summary, the FDA is set to grant full approval to Pfizer’s COVID-19 vaccine soon, with expectations that this will bolster vaccination rates and instigate new mandates across various sectors. As case numbers rise due to the delta variant, the urgency for this approval is more pronounced than ever.